Status:
TERMINATED
High Flow Nasal Cannula in Severe Sepsis
Lead Sponsor:
Althaia Xarxa Assistencial Universitària de Manresa
Conditions:
Severe Sepsis
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Severe sepsis leads a high morbidity and mortality by causing organ damage at distance. The treatment relies on early antibiotic therapy and hemodynamic resuscitation. Hypothesis: high flow nasal cann...
Detailed Description
Severe sepsis is a syndrome associated with severe infections with a high morbidity and mortality. In its most severe form, septic shock still leads to an in-hospital mortality of up to 50%. The patho...
Eligibility Criteria
Inclusion
- Patients \> 18 yr. with diagnostic criteria for severe sepsis, within 12 hours of admission in the Emergency Room, defined as hypotension after hemodynamic resuscitation, initial lactate \> 4, or persistence of organ dysfunction (oliguria \< 0.5 ml/kg/h, cyanosis, or altered consciousness).(qSOFA 1, 2 or 3)
Exclusion
- Patients who require immediate ventilatory support both invasive and non-invasive, defined by severe hypoxemia (PaO2/FiO2 \< 150), severe tachypnea (40 x') with signs of respiratory fatigue or low level of consciousness (Glasgow \< 8).
- Patients with limitation of the therapeutic effort or orders of not CPR.
- Patients not susceptible to treatment with HFNC (facial trauma, tracheostomized, rejection of previous treatments with HFNC).
- Participation in other clinical trials that may affect survival.
- Home treatment with oxygen, CPAP or Non-invasive ventilation.
Key Trial Info
Start Date :
January 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2020
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT03334227
Start Date
January 8 2018
End Date
December 28 2020
Last Update
January 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICU. Fundacio Althaia
Manresa, Barcelona, Spain, 08242